RxDoctor Payments Data

Carol Purcell, PA

Dermatology · Albuquerque, NMNPI 1043336126

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 421 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,188, 2.1 times the $1,064 reported in 2021. Among dermatology clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,855in general payments, 2019–2025

Across 421 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Sanofi$1K
  • Incyte Corporation$1K
  • Johnson & Johnson$1K
  • Novartis$846
  • Amgen$512
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$8,57697%
  • Education$2783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,855 in reported general payments places this provider in the 90th percentile of 52 dermatology providers in New Mexico.

See all dermatology providers in New Mexico

Medicare billing

Part B allowed, 2024
$94,286
Medicare patients
475
Services billed
1,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast16$73,657
Azelaic Acid28$2,554
Fluorouracil45$2,088
Doxycycline Hyclate63$1,272
Tacrolimus14$953
Mometasone Furoate42$801
Metronidazole15$685
Triamcinolone Acetonide48$677
Ketoconazole37$609
Fluocinolone Acetonide13$474
Econazole Nitrate14$423
Clindamycin Phosphate18$392
Minoxidil29$385
ValacyclovirValacyclovir Hcl15$315
Ciclopirox12$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$512$73,65716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 52 dermatology providers in New Mexico.

Other dermatology in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →